{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-089981","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.725528+00:00","generated_at":"2026-05-18T19:45:08.706944+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Tivic Health amends Statera license; may pay royalties in securities, directs up to $5.6M to Avenue Capital","bullets":["Amended license agreement gives Tivic discretion to pay future royalties in cash or its own securities.","Subsequent payments to Statera, up to $5.6M aggregate, will be paid directly to Avenue Capital on Statera's behalf.","Original exclusive license for Entolimod (TLR5 agonist) for Acute Radiation Syndrome and option for other indications unchanged.","License fee of $300K cash plus 945,785 common shares and convertible preferred shares already paid at closing in Feb 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-089981","json":"https://secwatch.observer/filing/0000950170-25-089981.json","markdown":"https://secwatch.observer/filing/0000950170-25-089981.md","text":"https://secwatch.observer/filing/0000950170-25-089981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025089981/0000950170-25-089981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025089981/tivc-20250618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:45:08.706944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}